NasdaqGS:XERSPharmaceuticals
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses
Xeris Biopharma Holdings, Inc. reported past second-quarter 2026 results with revenue rising to US$92.1 million from US$71.54 million a year earlier, while net loss widened to US$31.1 million from US$1.93 million and basic loss per share from continuing operations increased to US$0.18 from US$0.01.
Despite higher losses, the company also reported first-half 2026 revenue of US$175.23 million versus US$131.66 million and tightened its full-year 2026 total revenue guidance to US$385...